ClinicalTrials.gg

Program

SIM0518

A development code. Also written as “SIM0518+Bupropion”, “SIM0518+Midazolam” and “SIM0518+Repaglinide”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung, led by Simcere Pharmaceutical Group.

Furthest: phase 1, since Oct 22, 20261 company-led study, 1 open or runningNext primary completion: Dec 1, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Simcere Pharmaceutical Group11 open or runningphase 1since Oct 22, 2026Oct 22, 2026Dec 1, 2028phase 1 · NCT07912268

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 22, 2026First study: phase 1 study in Carcinoma, Non-Small-Cell LungFirst studyNCT07912268 · 270 planned · China

Ahead

  1. Dec 1, 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07912268

TargetBeta

ALK →ROS1 →read by rule
“SIM0518 is an oral, next-generation, highly selective ALK/ROS1 dual inhibitor.”study text, by rule · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
CrizotinibrulePfizerphase 431
repotrectinibruleBristol-Myers Squibbphase 39

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07912268Carcinoma, Non-Small-Cell Lung · China1Not yet recruitingDec 1, 2028270

How it is read

Names in the registry

  • “SIM0518”, 1 entry
  • “SIM0518+Bupropion”, 1 entry
  • “SIM0518+Midazolam”, 1 entry
  • “SIM0518+Repaglinide”, 1 entry
  • “SIM0518+Tolbutamide”, 1 entry

Codes read as this program: SIM0518.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.